Overview
Intravenous and oral ketamine represent opposite ends of the administration spectrum. IV ketamine delivers the drug directly into the bloodstream with near-complete bioavailability, while oral ketamine undergoes extensive first-pass liver metabolism, reducing bioavailability to approximately 17 to 24 percent. Despite this pharmacokinetic disadvantage, oral ketamine has gained significant traction through telehealth programs that provide supervised at-home treatment.
Pharmacokinetics
| Parameter | IV Ketamine | Oral Ketamine |
|---|---|---|
| Bioavailability | ~100 percent | 17 to 24 percent |
| Onset of action | 1 to 5 minutes | 30 to 60 minutes |
| Peak effect | 15 to 30 minutes | 60 to 90 minutes |
| Duration | 45 to 90 minutes | 3 to 6 hours |
| Primary metabolite | Norketamine | Norketamine (higher ratio) |
Oral administration produces significantly higher norketamine-to-ketamine ratios due to first-pass hepatic metabolism by CYP2B6 and CYP3A4 enzymes. Emerging research suggests norketamine may contribute its own antidepressant effects, potentially explaining why oral ketamine retains clinical efficacy despite lower parent drug levels.
Clinical Evidence
IV ketamine has the strongest evidence base, with over 40 randomized controlled trials documenting rapid antidepressant effects. The seminal studies by Berman et al. (2000) and Zarate et al. (2006) established IV ketamine's ability to reduce depressive symptoms within hours.
Oral ketamine evidence, while growing, is more limited. Smith-Apeldoorn et al. (2022) demonstrated that oral ketamine at doses of 0.5 to 1.0 mg/kg produced significant antidepressant responses, though onset was slower than IV. Jafarinia et al. (2016) found oral ketamine comparable to diclofenac for chronic pain.
Treatment Setting
IV ketamine requires a clinical setting with trained staff, continuous vital sign monitoring, and emergency equipment. Sessions typically last 40 to 60 minutes for the infusion plus 30 to 60 minutes of recovery observation.
Oral ketamine can be administered at home through telehealth programs, with video monitoring during sessions. For a detailed look at at-home ketamine safety, see our FAQ. Patients are typically observed via video call for the first 60 to 90 minutes and remain under instruction not to drive for 24 hours.
Cost Comparison
| Factor | IV Ketamine | Oral Ketamine |
|---|---|---|
| Per-session cost | $400 to $800 | $15 to $100 |
| Initial series (6 sessions) | $2,400 to $4,800 | $90 to $600 |
| Monthly maintenance | $400 to $1,600 | $150 to $350 |
| Insurance coverage | Rarely covered (off-label) | Rarely covered (off-label) |
Who Should Choose Which
IV ketamine is preferred for:
- Acute treatment-resistant depression requiring rapid response
- Patients with suicidal ideation needing urgent intervention
- Initial treatment to establish ketamine responsiveness
- Patients who want the strongest evidence-based approach
Oral ketamine is preferred for:
- Maintenance treatment after initial IV response
- Patients who cannot access or afford regular clinic visits
- Long-term management of chronic depression or pain
- Patients in areas without nearby ketamine clinics
References
- Berman et al. — First IV Ketamine Depression Study — Antidepressant effects of ketamine in depressed patients
- Zarate et al. — Ketamine RCT — Randomized trial of ketamine for treatment-resistant depression
- Smith-Apeldoorn et al. — Oral Ketamine Trial — Oral esketamine for treatment-resistant depression
- NIMH — Rapid-Acting Treatments — NIMH depression treatment information
Verdict
IV ketamine offers the strongest evidence base and highest bioavailability, making it the gold standard for acute treatment-resistant depression. Oral ketamine provides a more accessible, lower-cost maintenance option suitable for at-home use under medical supervision. Many treatment plans incorporate both: IV for initial response and oral for long-term maintenance.
Share